Abstract
Summary: When logarithmically growing neuroblastoma cells were exposed in vitro for 24 hr to a range of concentrations of various antitumour drugs and then cloned in agar to assess colony-forming ability, the dose-response curves obtained were of two types only, namely exponential—plateau or exponential. The former category, included hydroxyurea, 1,1′-propylene bispiperazine-3,5-dione (ICRF-159), vincristine and vindesine, where the plateau was reached before 1 log cell kill, and 4′-demethylepipodophllotoxin thenylidine glucoside (NSC 122819) (VM-26) and 4′-demethyl-epipodophllotoxin-9-(4,6-oethylidine-β-D-glucopyranoside (NSC 141540) (VP-16-213), where the plateau occurred at approximately 5% survival. Exponential survival curves were obtained with actinomycin D, Adriamycin, bleomycin, cis-dichlorodiammine platinum (II) (cis-platinum), dibromodulcitol, 5-fluorouracil, 4′-(9-acridiny-lamino)methanesulfon-m-anisidine (NSC 249992) (mAMSA), melphalan, and peptichemio. A comparison of drug concentrations required to reduce survival in vitro by 70%, with a 24-hr drug exposure, was attempted with those concentrations achievable as plasma levels in man after conventional drug therapy. The results obtained, after many and varied assumptions, allowed the division of the drugs tested into three main groups: (1) most effective agents, including mAMSA, VM-26, and Adriamycin; (2) agents with some activity—vincristine, vindesine, VP-16-213, cis-platinum, melphalan, and peptichemio, although only when the latter three drugs were used at the higher dosage levels; (3) agents with little, if any, activity—actinomycin D, bleomycin, dibromodulcitol, 5-fluorouracil, hydroxyurea, and ICRF-159. In terms of attempting clinical correlations, available data suggest definite value in treating neuroblastoma with VM-26 and Adriamycin [from our group (1)] and also with vincristine, melphalan (high dose), peptichemio, and cis-platinum [from our group (2)]. No significant clinical activity has been reported for actinomycin D nor for bleomycin in previously treated children, and both these drugs proved negative in this model test system. Among the newer agents tested experimentally, our results suggest that although clinical evaluation of mAMSA, VP-16-213, and vindesine might be profitable, dibromodulcitol and ICRF-159 may prove inactive.
Speculation: The dismal prognosis for the majority of children with neuroblastoma serves to highlight the need for new and more effective therapies. One approach is to attempt to screen experimentally in vitro for drugs effective in this disease. Our preliminary studies, using only one cell line derived from one portion of a human tumour, have suggested, with many reservations, some correlations between in vitro and clinical data. This work is now being extended to consider other human neuroblastoma cell lines and to monitor retrospectively drug responses in vitro with clinical responses. These studies are essential before any attempts are made to extrapolate any of the in vitro results to humans.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hill, B., Whelan, R. Assessments of the Sensitivities of Cultured Human Neuroblastoma Cells to Anti-Tumour Drugs. Pediatr Res 15, 1117–1122 (1981). https://doi.org/10.1203/00006450-198108000-00009
Issue Date:
DOI: https://doi.org/10.1203/00006450-198108000-00009
Keywords
This article is cited by
-
Uptake and release of iodine-labelled m-iodobenzylguanidine in a neuroblastoma cell culture system and its importance in neuroblastoma therapy
Journal of Cancer Research and Clinical Oncology (1989)
-
Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening
Investigational New Drugs (1988)
-
Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line
Urological Research (1985)
-
Phase I and II study of AMSA in childhood tumours
Cancer Chemotherapy and Pharmacology (1982)